New TP53 MASTR

New TP53 MASTR

Molecular Biology

September 29, 2015

Multiplicom is pleased to announce the release of the TP53 MASTR molecular assay, research use only, for the identification of mutations in the entire coding region of TP53.

TP53 is the most frequently mutated gene in cancer and is associated with Li-Fraumeni syndrome, an inherited cancer syndrome. The TP53 MASTR is designed for intended use both on germline material as well as FFPE material.
NGS-based analysis of TP53 mutations has a wide variety of clinical and research applications.

Germline mutation detection

  • for cancer predisposition testing (e.g. Li-Fraumeni syndrome)

Somatic mutation detection

  • for molecular tumor classification and as prognostic biomarker (including leukemia (e.g. CLL, Non-Hodgekin lymphoma), sarcomas, bladder and esophageal cancer)
  • for prediction of therapeutic success (e.g. TP53-targeting drugs and MDM2 inhibitors)
  • for clonality analysis to discriminate primary tumors and metastases

 

The TP53 MASTR has several advantages:

  • clear clinical guidelines to use the test
  • compatible with DNA derived from both FFPE tumor samples and blood

RIDASCREEN FAST Macadamia

RIDASCREEN FAST Macadamia

Molecular Biology

R-Biopharm offers a sandwich enzyme immunoassay for the quantitative analysis of macadamia nut in raw and processed food such as bakery products, ice cream, cereals and chocolate. The limit of detection of RIDASCREEN®FAST Macadamia (product code R6852) is 0.64 ppm (mg/kg).

June 01, 2013 More +
Simple new prenatal blood test for early and accurate detection of major chromosomal abnormalities

Simple new prenatal blood test for early and accurate detection of major chromosomal abnormalities

Molecular Biology

Multiplicom is proud to launch Clarigo™, a new CE-IVD1 non-invasive prenatal test (NIPT). This highly accurate blood test will enable genetic analysis laboratories to detect the presence or absence of major chromosomal abnormalities such as trisomy 21 (Down’s syndrome), 18 (Edwards’ syndrome) and 13 (Patau syndrome), in the fetus, as early as in the first trimester of pregnancy by analysis of the fetus’s DNA in the maternal blood.

October 22, 2015 More +
Ready to make an enquiry Call us on: + 961 1 39 66 77
Or email us